Y10S 977/911
Cancer cell destruction
Y10S977/911 (Cancer cell destruction) appears on 74 US grants and 61 published applications in this corpus.
Search patents in Y10S- Granted patents
- 74
- Published applications
- 61
- Assignees
- 49
- Inventors
- 163
- Latest grant
- 6 Aug 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 0 | 0 |
| 1999 | 5 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 1 |
| 2002 | 2 | 4 |
| 2003 | 10 | 3 |
| 2004 | 1 | 3 |
| 2005 | 2 | 5 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 2 | 3 |
| 2009 | 4 | 5 |
| 2010 | 2 | 3 |
| 2011 | 2 | 4 |
| 2012 | 5 | 8 |
| 2013 | 5 | 6 |
| 2014 | 4 | 7 |
| 2015 | 3 | 2 |
| 2016 | 9 | 2 |
| 2017 | 3 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer6 Aug 2019US 10,369,113 B2The Johns Hopkins University
- Cancer cell targeting using nanoparticles11 Sep 2018US 10,071,056 B2Pfizer Inc.
- Silicon nanoparticle for photodynamic cancer treatment utilizing quantum dot optical properties14 Mar 2017US 9,592,292 B1
- Redox active cerium oxide nanoparticles and associated methods7 Mar 2017US 9,585,840 B1University of Central Florida Research Foundation, Inc.
- Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers3 Jan 2017US 9,532,949 B2Stc. Unm
- Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer4 Jun 2020US 2020/0170960 A1The Johns Hopkins University
- Synthesis of silver nanoparticles using sesame oil cake22 Nov 2018US 2018/0333433 A1King Saud University
- Polymerizable quantum dot nanoparticles and their use as therapeutic, ablation and tattooing agents5 Apr 2018US 2018/0092815 A1Nanoco Technologies Ltd.
- Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer18 May 2017US 2017/0135961 A1The Johns Hopkins University
- Cancer cell targeting using nanoparticles22 Dec 2016US 2016/0367481 A1BIND Therapeutics, Inc.
Most cited
By later US patents
- Glucagon-like insulinotropic peptide analogs, compositions, and methods of use238US 5,512,549 AEli Lilly and Company · 1996
- Compositions and methods of delivery of pharmacological agents161US 7,820,788 B2Abraxis BioScience, LLC · 2010
- Compositions and methods of delivery of pharmacological agents146US 8,138,229 B2Abraxis BioScience, LLC · 2012
- Compositions and methods of delivery of pharmacological agents131US 7,923,536 B2Abraxis BioScience, LLC · 2011
- Compositions and methods of delivery of pharmacological agents128US 8,314,156 B2Abraxis BioScience, LLC · 2012